Nivolumab in combination with relatlimab significantly improved PFS in patients with previously untreated metastatic or unresectable melanoma
The phase 2/3 RELATIVITY-047 trial shows, that a combination of nivolumab & relatlimab significantly improved the primary endpoint of progression-free survival (PFS) versus monotherapy with nivolumab in patients with previously untreated metastatic or unresectable melanoma.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
